Literature DB >> 28941139

Comparative outcomes of transcatheter aortic valve replacement in African American and Caucasian patients with severe aortic stenosis.

Fahad Alqahtani1, Sami Aljohani1, Ahmad Almustafa1, Mohammed Alhijji2, Oluseun Ali3, David R Holmes2, Mohamad Alkhouli1,2.   

Abstract

BACKGROUND: Racial disparities in cardiovascular care have been extensively investigated. The introduction of transcatheter aortic valve replacement (TAVR) revolutionized the treatment of aortic stenosis (AS) in the last decade. Whether a racial disparity in the utilization and outcome of TAVR exists is unknown.
METHODS: We utilized the nationwide inpatient sample (NIS) to compare utilization rates, and in-hospital outcomes of Caucasians and African American (AA) patients who underwent TAVR between August 2011 and December 2014.
RESULTS: A total of 7,176 patients (6870 Caucasians, 95.7%) and (306 AAs, 4.3%) were included in this analysis. Among patients who underwent aortic valve replacement between 2011 and 2014, the rates of TAVR utilization increased from 0.32% to 7.6% in AAs and from 0.4% to 8.8% in Caucasians. In propensity-matched cohorts of patients (n = 300 Caucasians and n = 300 AAs), in-hospital mortality was similar (3.7% and 3.3%, respectively, P = 0.99). Also, rates of key complications including stroke, permanent pacemaker implantation (PPMI), vascular complications, acute kidney injury, new dialysis, blood transfusion, and tamponade were similar in both races. There was also no significant difference between Caucasians and AAs with regards to length of stay, cost of hospitalization, and intermediate care facility utilization.
CONCLUSIONS: There was no significant difference in the utilization rates, in-hospital outcomes, and cost of TAVR between Caucasians and AA patients in contemporary US practice. Further comparative studies of surgical and TAVR in AAs and other racial minorities are warranted.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  aortic stenosis; comparative outcomes; racial disparity; transcathter aortic valve replacement

Mesh:

Year:  2017        PMID: 28941139     DOI: 10.1002/ccd.27257

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  A review of racial disparities in transcatheter aortic valve replacement (TAVR): accessibility, referrals and implantation.

Authors:  Tamunoinemi Bob-Manuel; Arindam Sharma; Amit Nanda; Devarshi Ardeshna; William Paul Skelton; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2018-01

2.  Racial/Ethnic Disparities in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights from the Healthcare Cost and Utilization Project's National Inpatient Sample.

Authors:  Dagmar F Hernandez-Suarez; Sagar Ranka; Pedro Villablanca; Nicole Yordan-Lopez; Lorena González-Sepúlveda; Jose Wiley; Cristina Sanina; Abiel Roche-Lima; Brenda G Nieves-Rodriguez; Stacey Thomas; Pedro Cox-Alomar; Angel Lopez-Candales; Harish Ramakrishna
Journal:  Cardiovasc Revasc Med       Date:  2019-04-09

3.  Racial Disparities in the Utilization and Outcomes of Structural Heart Disease Interventions in the United States.

Authors:  Mohamad Alkhouli; Fahad Alqahtani; David R Holmes; Chalak Berzingi
Journal:  J Am Heart Assoc       Date:  2019-07-18       Impact factor: 5.501

4.  Temporal trends in transcatheter aortic valve replacement use and outcomes by race, ethnicity, and sex.

Authors:  Celina M Yong; Karolina Jaluba; Wayne Batchelor; Santosh Gummipundi; Steven M Asch; Paul Heidenreich
Journal:  Catheter Cardiovasc Interv       Date:  2022-04-08       Impact factor: 2.585

5.  Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era.

Authors:  J Matthew Brennan; Martin B Leon; Paige Sheridan; Isabel J Boero; Qinyu Chen; Angela Lowenstern; Vinod Thourani; Sreekanth Vemulapalli; Kevin Thomas; Tracy Y Wang; Eric D Peterson
Journal:  J Am Heart Assoc       Date:  2020-08-11       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.